메뉴 보기
link 세부 정보
정보 바로가기 : Samsung Bioepis joins denosumab battle with FDA, EU nod as Amgen's $5.5-b...
Samsung Bioepis joins denosumab battle with FDA, EU nod as Amgen's $5.5-b...[카테고리 설정이 아직되어 있지 않습니다.]
The phase 3 trial in postmenopausal osteoporosis patients met its primary endpoint, showing comparable changes in lumbar spine bone mineral density (BMD) at 12 months, with 18-month follow-up...
